LGND Stock Overview
A biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ligand Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$101.14 |
| 52 Week High | US$112.13 |
| 52 Week Low | US$49.24 |
| Beta | 0.91 |
| 11 Month Change | 0.98% |
| 3 Month Change | 27.17% |
| 1 Year Change | 60.41% |
| 33 Year Change | -26.08% |
| 5 Year Change | 3.80% |
| Change since IPO | 68.56% |
Recent News & Updates
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18
Recent updates
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Shareholder Returns
| LGND | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.4% | -3.1% | -4.4% |
| 1Y | 60.4% | 16.1% | 19.1% |
Return vs Industry: LGND exceeded the US Pharmaceuticals industry which returned 16.1% over the past year.
Return vs Market: LGND exceeded the US Market which returned 19.1% over the past year.
Price Volatility
| LGND volatility | |
|---|---|
| LGND Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LGND has not had significant price volatility in the past 3 months.
Volatility Over Time: LGND's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 58 | Todd Davis | www.ligand.com |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
Ligand Pharmaceuticals Incorporated Fundamentals Summary
| LGND fundamental statistics | |
|---|---|
| Market cap | US$1.85b |
| Earnings (TTM) | US$42.14m |
| Revenue (TTM) | US$133.48m |
43.8x
P/E Ratio13.8x
P/S RatioIs LGND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGND income statement (TTM) | |
|---|---|
| Revenue | US$133.48m |
| Cost of Revenue | US$33.33m |
| Gross Profit | US$100.14m |
| Other Expenses | US$58.00m |
| Earnings | US$42.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.31 |
| Gross Margin | 75.03% |
| Net Profit Margin | 31.57% |
| Debt/Equity Ratio | 0% |
How did LGND perform over the long term?
See historical performance and comparison